Evommune EVMN
NYSE EVMN
$8.64 +0.80 (+10.14%)
As of: Nov 11, 2026 · 3:59 PM EST

Evommune (EVMN) Common Equity (2024 - 2026)

Updated

Evommune's Common Equity was $277.59 million in Q2 2026, compared with -$171.23 million a year earlier and down 8.9% from the prior quarter.

Analysis

Evommune (EVMN) Common Equity (2024 - 2026) Analysis & Trends

At the end of FY2025, Common Equity at Evommune came in at $205.57 million.

  • In earlier years, Common Equity was -$144.24 million in FY2024.
  • Quarterly Common Equity has moved between -$183.14 million (Q3 2025) and $304.56 million (Q1 2026) over five years.
  • Per Business Quant data, EVMN's Common Equity in the three quarters before Q2 2026 was $304.56 million (Q1 2026), $205.57 million (Q4 2025) and -$183.14 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Common Equity (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 40.27 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 81.53 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -4.58 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 44.95 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 51.81 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 14.35 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 13.04 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 89.30 Bn
10 Evommune 285.17 Mn -352.34 Mn - 277.59 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 277.59 Mn
Mar 31, 2026 304.56 Mn
Dec 31, 2025 205.57 Mn
Sep 30, 2025 -183.14 Mn
Jun 30, 2025 -171.23 Mn
Mar 31, 2025 -158.24 Mn
Dec 31, 2024 -144.24 Mn
Sep 30, 2024 -122.53 Mn
API Access

Evommune Common Equity API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=common-equity&ticker=EVMN&period=max&api_key=YOUR_API_KEY